Study analysis · Aging Cell · 2024
Being 'metabolically older' AND obese was linked to the highest relative risk of death and 32 diseases — but even normal-weight people with accelerated metabolic aging weren't safe.
In a 12.6-year study of 85,458 UK adults, people whose blood metabolism looked older than their age had higher relative risks of death and obesity-related diseases, and the combination with obesity was worst — though absolute risk increases weren't reported.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study followed a large group of people for many years to see if certain body weight and aging markers were linked to health problems. It can show that these things often go together, but it cannot prove that one thing causes the other. So we can say they are connected, but not that one directly causes the other.
What’s the bottom line?
In a large UK study, people were grouped by body size and a blood test that estimates metabolic age. Those who were both metabolically older and obese had the highest risk of death and many obesity-related diseases over about 12.6 years.
How strong is this study?
The study is very large and followed people for a long time, which makes its patterns fairly reliable. But because people were not randomly assigned to different groups, other hidden differences could still explain the links. So we can trust the connections it finds, but we should be careful about saying what caused them.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=85458)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a prospective observational cohort study without randomization. Although it has a large sample, long follow-up, and covariate adjustment, it cannot control for unmeasured or residual confounding. Therefore, it can demonstrate associations and risk stratification but cannot establish cause-effect relationships.
COI Unknown
Could not determine conflict of interest status
The provided text is truncated and does not include a conflict of interest or funding statement, so COI and funding cannot be fully assessed.
The excerpt ends mid-sentence in the Results section; no COI or funding section is included. The study uses UK Biobank data (application 101032) and reports ethical approval. Author affiliations and industry ties are not provided.
Key takeaways
- 01
Compared with metabolically younger normal-weight people, metabolically older obese people had higher relative risk of death and 32 obesity-related diseases.
- 02
Metabolically older overweight had death plus 27 diseases; metabolically younger obese had death plus 26; metabolically younger overweight had 21; metabolically older normal weight had death plus 14.
- 03
The study did not report absolute risk increases (e.g., extra cases per 1,000 people).
- 04
The study reports relative risks only; absolute risks were not reported, so we cannot say exactly how many extra cases per 1,000 people.
- 05
The pattern shows that being metabolically older adds risk even at normal weight, and obesity adds risk even without metabolic aging.
- 06
The combination is worst.
Surprising findings
- Normal-weight people with accelerated metabolomic aging still had higher relative risk of mortality and 14 obesity-related morbidities.Many people assume normal BMI equals low risk, but this shows metabolic aging can signal risk independently of weight.
- Obese people without accelerated metabolomic aging still had increased relative risk of mortality and 26 obesity-related morbidities.It challenges the 'metabolically healthy obesity' concept as a benign state.
- Inflammation mediated up to 76.55% of the association between MY-OB and all-cause mortality.A single inflammatory score explained most of the mortality risk in that group, highlighting inflammation as a major pathway.
- Additive interaction between metabolomic aging and obesity accounted for 16.35% to 49.65% of the risk for CVD mortality and 10 morbidities.The combined effect is not just additive — up to half the risk in some conditions may come from the interaction itself.
Practical takeaways
If you are overweight or obese, weight management is likely beneficial regardless of whether your metabolic age appears younger.
This is observational; weight loss itself was not tested here. Absolute risk reduction is unknown.
medium confidenceIf you have a normal BMI but signs of accelerated metabolic aging, don't assume you're low risk — focus on metabolic health through diet, exercise, and sleep.
Metabolomic aging testing is not routine; the study used 168 metabolites and a specific age-gap definition.
medium confidenceReducing chronic low-grade inflammation through lifestyle may help lower risk, especially if you are overweight or obese.
Mediation analysis is observational; inflammation was measured with INFLA-score, not a direct intervention target.
low-to-medium confidenceAsk for a holistic risk assessment that goes beyond BMI if you have concerns about metabolic aging.
Metabolomic age is not yet standard in clinics and may not be covered by insurance.
low confidenceWhy this study matters
Six phenotypes, one clear gradient
Compared with metabolomically younger normal weight (MY-NW), the metabolomically older obese (MO-OB) group had increased relative risk of mortality and 32 out of 43 obesity-related morbidities. The gradient followed: MO-OB (mortality + 32 ORMs), MO-OW (mortality + 27 ORMs), MY-OB (mortality + 26 ORMs), MY-OW (21 ORMs), and MO-NW (mortality + 14 ORMs).
It shows two separate risk axes — body weight and metabolic aging — can combine to stratify who gets sickest.
Normal weight but metabolically older is not low risk
Even among normal-weight participants, those with metabolomic aging acceleration (MO-NW) had increased relative risk of all-cause mortality and 14 obesity-related morbidities compared with MY-NW. The study notes: 'individuals with metabolomic aging acceleration had higher mortality and cardiovascular risk, even within the same BMI category.'
It challenges the assumption that normal BMI automatically means healthy.
Obesity alone matters — even without accelerated metabolic aging
The MY-OB phenotype (metabolomically younger but obese) still had increased relative risk of mortality and 26 obesity-related morbidities compared with MY-NW. The authors conclude: 'Weight management should also be extended to individuals with overweight or obesity even in the absence of accelerated metabolomic aging.'
It pushes back on the idea that 'metabolically healthy obesity' is harmless.
Additive interaction: the whole is worse than the sum
Additive interactions between metabolomic aging acceleration and obesity were found for CVD-specific mortality and 10 obesity-related morbidities, including heart failure, aortic valve stenosis, stomach cancer, depression, NAFLD, chronic liver disease, asthma, sleep apnea, CKD, and psoriasis. The proportion attributable to interaction ranged from 16.35% to 49.65%.
It means the combined effect of both risk factors is greater than adding them separately — a true synergy.
Inflammation may explain a big chunk of risk
Chronic low-grade inflammation, measured by the INFLA-score, partially mediated the association between metabolomically younger overweight/obesity and adverse outcomes. For MY-OB, mediation proportions ranged from 8.12% for cholelithiasis to 76.55% for all-cause mortality.
It gives a biological mechanism: inflammation may be a key link between excess weight and death risk, even when metabolism looks younger.
No absolute risk increases were reported
The study reports relative risks only and explicitly states that absolute risk increases were not reported. This means we cannot say exactly how many extra cases per 1,000 people occurred over the 12.6-year follow-up.
It's a crucial caveat for interpreting scary-sounding relative risks.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In a large UK study, people were grouped by body size and a blood test that estimates metabolic age. Those who were both metabolically older and obese had the highest risk of death and many obesity-related diseases over about 12.6 years.
Research results
Compared with metabolically younger normal-weight people, metabolically older obese people had higher relative risk of death and 32 obesity-related diseases. Metabolically older overweight had death plus 27 diseases; metabolically younger obese had death plus 26; metabolically younger overweight had 21; metabolically older normal weight had death plus 14. The study did not report absolute risk increases (e.g., extra cases per 1,000 people).
What this means - more context
The study reports relative risks only; absolute risks were not reported, so we cannot say exactly how many extra cases per 1,000 people. The pattern shows that being metabolically older adds risk even at normal weight, and obesity adds risk even without metabolic aging. The combination is worst.
To investigate the association between metabolomic aging acceleration and body mass index (BMI) phenotypes with mortality and obesity-related morbidities.
In a prospective cohort of 85,458 UK Biobank participants followed for a median of 12.6 years, six phenotypes were defined by metabolomic aging (younger/older) and BMI (normal weight, overweight, obesity). Compared with metabolomically younger normal weight (MY-NW), the metabolomically older obese (MO-OB) phenotype had the highest relative risk of mortality and 32 out of 43 obesity-related morbidities, followed by MO-OW (mortality + 27 morbidities), MY-OB (mortality + 26), MY-OW (21), and MO-NW (mortality + 14). Additive interactions between metabolomic aging acceleration and obesity were found for CVD-specific mortality and 10 obesity-related morbidities, with the proportion attributable to interaction ranging from 16.35% to 49.65%. Absolute risk increases were not reported in this study.
Methods Used
Prospective cohort study using UK Biobank data. 85,458 participants after exclusions. Metabolomic age was predicted from 168 metabolites; chronological age-adjusted age gap >0 defined metabolomically older (MO), <0 defined metabolomically younger (MY). BMI categories: normal weight (<25 kg/m2), overweight (25–<30), obesity (≥30). Six MAA-BMI phenotypes compared. Outcomes: all-cause, CVD-specific, and cancer-specific mortality plus 43 obesity-related morbidities from death registries and hospital records. Cox proportional hazards models adjusted for covariates and controlled for false discovery rate. Mediation analysis used INFLA-score for chronic low-grade inflammation.
Main Finding
Compared with MY-NW, the MO-OB phenotype had increased relative risk of mortality and 32 obesity-related morbidities, MO-OW had mortality and 27 morbidities, MY-OB had mortality and 26 morbidities, MY-OW had 21 morbidities, and MO-NW had mortality and 14 morbidities. Additive interaction between metabolomic aging acceleration and obesity was observed for CVD-specific mortality and 10 obesity-related morbidities, with proportion attributable to interaction ranging from 16.35% to 49.65%. Within each BMI category, metabolomically older individuals had higher relative risks of mortality and several morbidities. Absolute risk increases were not reported in this study.
Confidence Level
Moderate to high: large prospective cohort with long follow-up, comprehensive outcomes, and consistent sensitivity analyses. Limitations include observational design, self-reported covariates, baseline-only metabolomic measurement, possible reverse causality, and missing mild/undiagnosed cases from hospital records.
Study Flags
Red Flags
- •Observational design cannot prove causation; residual confounding possible.
- •Covariates such as lifestyle factors were self-reported and subject to recall bias.
- •Metabolomic aging was measured only at baseline; changes over time were not assessed.
Surprising Findings
Normal-weight people with accelerated metabolomic aging still had higher relative risk of mortality and 14 obesity-related morbidities.
Many people assume normal BMI equals low risk, but this shows metabolic aging can signal risk independently of weight.
Practical Takeaways
If you are overweight or obese, weight management is likely beneficial regardless of whether your metabolic age appears younger.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study followed a large group of people for many years to see if certain body weight and aging markers were linked to health problems. It can show that these things often go together, but it cannot prove that one thing causes the other. So we can say they are connected, but not that one directly causes the other.
Strengths
- Large sample size (85,458 participants)
- Prospective cohort design with long median follow-up (~12.6 years)
- Comprehensive assessment of 43 obesity-related morbidities plus mortality outcomes
Weaknesses
- Observational design without randomization; cannot establish causation
- No blinding of participants or outcome assessors (though objective outcomes reduce this concern)
- Residual confounding from unmeasured factors
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In a large UK study, people were grouped by body size and a blood test that estimates metabolic age. Those who were both metabolically older and obese had the highest risk of death and many obesity-related diseases over about 12.6 years.
Research results
Compared with metabolically younger normal-weight people, metabolically older obese people had higher relative risk of death and 32 obesity-related diseases. Metabolically older overweight had death plus 27 diseases; metabolically younger obese had death plus 26; metabolically younger overweight had 21; metabolically older normal weight had death plus 14. The study did not report absolute risk increases (e.g., extra cases per 1,000 people).
What this means - more context
The study reports relative risks only; absolute risks were not reported, so we cannot say exactly how many extra cases per 1,000 people. The pattern shows that being metabolically older adds risk even at normal weight, and obesity adds risk even without metabolic aging. The combination is worst.
To investigate the association between metabolomic aging acceleration and body mass index (BMI) phenotypes with mortality and obesity-related morbidities.
In a prospective cohort of 85,458 UK Biobank participants followed for a median of 12.6 years, six phenotypes were defined by metabolomic aging (younger/older) and BMI (normal weight, overweight, obesity). Compared with metabolomically younger normal weight (MY-NW), the metabolomically older obese (MO-OB) phenotype had the highest relative risk of mortality and 32 out of 43 obesity-related morbidities, followed by MO-OW (mortality + 27 morbidities), MY-OB (mortality + 26), MY-OW (21), and MO-NW (mortality + 14). Additive interactions between metabolomic aging acceleration and obesity were found for CVD-specific mortality and 10 obesity-related morbidities, with the proportion attributable to interaction ranging from 16.35% to 49.65%. Absolute risk increases were not reported in this study.
Methods Used
Prospective cohort study using UK Biobank data. 85,458 participants after exclusions. Metabolomic age was predicted from 168 metabolites; chronological age-adjusted age gap >0 defined metabolomically older (MO), <0 defined metabolomically younger (MY). BMI categories: normal weight (<25 kg/m2), overweight (25–<30), obesity (≥30). Six MAA-BMI phenotypes compared. Outcomes: all-cause, CVD-specific, and cancer-specific mortality plus 43 obesity-related morbidities from death registries and hospital records. Cox proportional hazards models adjusted for covariates and controlled for false discovery rate. Mediation analysis used INFLA-score for chronic low-grade inflammation.
Main Finding
Compared with MY-NW, the MO-OB phenotype had increased relative risk of mortality and 32 obesity-related morbidities, MO-OW had mortality and 27 morbidities, MY-OB had mortality and 26 morbidities, MY-OW had 21 morbidities, and MO-NW had mortality and 14 morbidities. Additive interaction between metabolomic aging acceleration and obesity was observed for CVD-specific mortality and 10 obesity-related morbidities, with proportion attributable to interaction ranging from 16.35% to 49.65%. Within each BMI category, metabolomically older individuals had higher relative risks of mortality and several morbidities. Absolute risk increases were not reported in this study.
Confidence Level
Moderate to high: large prospective cohort with long follow-up, comprehensive outcomes, and consistent sensitivity analyses. Limitations include observational design, self-reported covariates, baseline-only metabolomic measurement, possible reverse causality, and missing mild/undiagnosed cases from hospital records.
Study Flags
Red Flags
- •Observational design cannot prove causation; residual confounding possible.
- •Covariates such as lifestyle factors were self-reported and subject to recall bias.
- •Metabolomic aging was measured only at baseline; changes over time were not assessed.
Surprising Findings
Normal-weight people with accelerated metabolomic aging still had higher relative risk of mortality and 14 obesity-related morbidities.
Many people assume normal BMI equals low risk, but this shows metabolic aging can signal risk independently of weight.
Practical Takeaways
If you are overweight or obese, weight management is likely beneficial regardless of whether your metabolic age appears younger.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study followed a large group of people for many years to see if certain body weight and aging markers were linked to health problems. It can show that these things often go together, but it cannot prove that one thing causes the other. So we can say they are connected, but not that one directly causes the other.
Strengths
- Large sample size (85,458 participants)
- Prospective cohort design with long median follow-up (~12.6 years)
- Comprehensive assessment of 43 obesity-related morbidities plus mortality outcomes
Weaknesses
- Observational design without randomization; cannot establish causation
- No blinding of participants or outcome assessors (though objective outcomes reduce this concern)
- Residual confounding from unmeasured factors
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study is very large and followed people for a long time, which makes its patterns fairly reliable. But because people were not randomly assigned to different groups, other hidden differences could still explain the links. So we can trust the connections it finds, but we should be careful about saying what caused them.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=85458)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a prospective observational cohort study without randomization. Although it has a large sample, long follow-up, and covariate adjustment, it cannot control for unmeasured or residual confounding. Therefore, it can demonstrate associations and risk stratification but cannot establish cause-effect relationships.
COI Unknown
Could not determine conflict of interest status
The provided text is truncated and does not include a conflict of interest or funding statement, so COI and funding cannot be fully assessed.
The excerpt ends mid-sentence in the Results section; no COI or funding section is included. The study uses UK Biobank data (application 101032) and reports ethical approval. Author affiliations and industry ties are not provided.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
10 researchersIf this is your work, this is how we attribute it on Fit Body Science. Xiaomin Zeng is listed as the lead author.